- Home
- GLRE vs ASMB Comparison
GLRE vs ASMB Comparison
Compare GLRE & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | ASMB |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.9M | 512.1M |
| IPO Year | 2007 | 2010 |
Fundamental Metrics
Financial Performance| Metric | GLRE | ASMB |
|---|---|---|
| Price | $15.48 | $247.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.20 |
| AVG Volume (30 Days) | 130.1K | ★ 221.7K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 75.00 | ★ 91.78 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $729,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $638.39 |
| P/E Ratio | $86.22 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $20.23 |
| 52 Week High | $19.39 | $39.71 |
Technical Indicators
Market Signals| Indicator | GLRE | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 42.33 | 73.33 |
| Support Level | $14.57 | $25.86 |
| Resistance Level | $17.05 | $39.17 |
| Average True Range (ATR) | 0.37 | 1.79 |
| MACD | -0.01 | 0.79 |
| Stochastic Oscillator | 24.55 | 97.91 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.